Answers are grounded in this paper and cite their sources.
Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Objective: The 52-week, phase 3b/4 PSORIATYK SCALP (NCT05478499) trial evaluated deucravacitinib efficacy and safety in scalp psoriasis, including patients with more limited overall psoriasis. Here, we report week 16 results. Methods: = 103) through week 16. The primary efficacy endpoint was scalp-specific Physician Global Assessment score of 0/1; key secondary endpoints were Psoriasis Scalp Severity Index 90, scalp-specific numeric rating scale itch score, and static Physician Global Assessment (sPGA) 0/1. Adverse events were comparable between groups. Limitations: 16-week analysis. Conclusion: Deucravacitinib was efficacious and well tolerated in patients with moderate to severe scalp psoriasis.
No takes yet. Share an insight, caveat, or question.
Duffin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: